214 related articles for article (PubMed ID: 31346082)
21. Sangivamycin induces apoptosis by suppressing Erk signaling in primary effusion lymphoma cells.
Wakao K; Watanabe T; Takadama T; Ui S; Shigemi Z; Kagawa H; Higashi C; Ohga R; Taira T; Fujimuro M
Biochem Biophys Res Commun; 2014 Feb; 444(2):135-40. PubMed ID: 24434142
[TBL] [Abstract][Full Text] [Related]
22. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
[TBL] [Abstract][Full Text] [Related]
23. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
[TBL] [Abstract][Full Text] [Related]
24. Cdk1 inhibition induces mutually inhibitory apoptosis and reactivation of Kaposi's sarcoma-associated herpesvirus.
Li X; Chen S; Sun R
J Virol; 2012 Jun; 86(12):6668-76. PubMed ID: 22496227
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
Saji C; Higashi C; Niinaka Y; Yamada K; Noguchi K; Fujimuro M
Biochem Biophys Res Commun; 2011 Dec; 415(4):573-8. PubMed ID: 22074820
[TBL] [Abstract][Full Text] [Related]
26. Arctigenin induces the apoptosis of primary effusion lymphoma cells under conditions of glucose deprivation.
Baba Y; Shigemi Z; Hara N; Moriguchi M; Ikeda M; Watanabe T; Fujimuro M
Int J Oncol; 2018 Feb; 52(2):505-517. PubMed ID: 29207179
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
28. Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.
Mediani L; Gibellini F; Bertacchini J; Frasson C; Bosco R; Accordi B; Basso G; Bonora M; Calabrò ML; Mattiolo A; Sgarbi G; Baracca A; Pinton P; Riva G; Rampazzo E; Petrizza L; Prodi L; Milani D; Luppi M; Potenza L; De Pol A; Cocco L; Capitani S; Marmiroli S
Oncotarget; 2016 Feb; 7(5):5521-37. PubMed ID: 26575168
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
Paul AG; Chandran B; Sharma-Walia N
Transl Res; 2013 Aug; 162(2):77-92. PubMed ID: 23567332
[TBL] [Abstract][Full Text] [Related]
30. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma.
Carbone A; Gloghini A; Vaccher E; Cerri M; Gaidano G; Dalla-Favera R; Tirelli U
J Mol Diagn; 2005 Feb; 7(1):17-27. PubMed ID: 15681470
[TBL] [Abstract][Full Text] [Related]
31. EphA7 Functions as Receptor on BJAB Cells for Cell-to-Cell Transmission of the Kaposi's Sarcoma-Associated Herpesvirus and for Cell-Free Infection by the Related Rhesus Monkey Rhadinovirus.
Großkopf AK; Schlagowski S; Hörnich BF; Fricke T; Desrosiers RC; Hahn AS
J Virol; 2019 Aug; 93(15):. PubMed ID: 31118261
[TBL] [Abstract][Full Text] [Related]
32. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
Zhang YJ; Patel D; Nan Y; Fan S
Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
[TBL] [Abstract][Full Text] [Related]
34. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.
Carbone A; Cesarman E; Gloghini A; Drexler HG
AIDS; 2010 Feb; 24(4):479-90. PubMed ID: 20051807
[TBL] [Abstract][Full Text] [Related]
35. Evidence for Multiple Subpopulations of Herpesvirus-Latently Infected Cells.
Landis JT; Tuck R; Pan Y; Mosso CN; Eason AB; Moorad R; Marron JS; Dittmer DP
mBio; 2022 Feb; 13(1):e0347321. PubMed ID: 35089062
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma.
Lam BQ; Dai L; Li L; Qiao J; Lin Z; Qin Z
Oncotarget; 2017 Mar; 8(11):18373-18380. PubMed ID: 28407694
[TBL] [Abstract][Full Text] [Related]
37. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.
Manzano M; Günther T; Ju H; Nicholas J; Bartom ET; Grundhoff A; Gottwein E
mBio; 2020 Aug; 11(4):. PubMed ID: 32843547
[TBL] [Abstract][Full Text] [Related]
38. Diallyl trisulfide induces apoptosis by suppressing NF-κB signaling through destabilization of TRAF6 in primary effusion lymphoma.
Shigemi Z; Furukawa Y; Hosokawa K; Minami S; Matsuhiro J; Nakata S; Watanabe T; Kagawa H; Nakagawa K; Takeda H; Fujimuro M
Int J Oncol; 2016 Jan; 48(1):293-304. PubMed ID: 26647777
[TBL] [Abstract][Full Text] [Related]
39. Nigericin Induces Apoptosis in Primary Effusion Lymphoma Cells by Mitochondrial Membrane Hyperpolarization and β-Catenin Destabilization.
Umeyama H; Shigemi Z; Baba Y; Hara N; Watanabe T; Fujimuro M
Anticancer Res; 2023 Jun; 43(6):2455-2465. PubMed ID: 37247906
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
